| sofosbuvir/velpatasvir / Generic mfg. |
| Unknown status | N/A | 10000 | RoW | Sofosbuvir+Ledipasvir, Harvoni (generic), Sofosbuvir+Daclatasvir, Sovaldi (generic), Daklinza (generic), Sofosbuvir+Velpatasvir, Epclusa (generic) | FixHepC | Hepatitis C | 01/17 | 06/18 | | |
NCT04047680: eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs |
|
|
| Completed | N/A | 441 | RoW | Sofosbuvir / Velpatasvir Oral Tablet, Epclusa, Sofosbuvir and Ledipasvir, Harvoni, Sofosbuvir Tablets, Solvadi, Ombitasvir/paritaprevir/ritonavir, Viekirax/exviera, Elbasvir / Grazoprevir Oral Tablet, Zepatier, Glecaprevir and Pibrentasvir, Maviret | National Taiwan University Hospital | Hepatitis C, Renal Disease, Viral Hepatitis C | 12/18 | 06/19 | | |
DASH, NCT03164902: Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence |
|
|
| Unknown status | N/A | 253 | US | Digital Medicine | Proteus Digital Health, Inc. | Hepatitis C, Chronic, Nonadherence, Patient | 04/19 | 04/19 | | |
NCT03570112: Transmission of Chronic Hepatitis C in Pregnancy |
|
|
| Completed | N/A | 40 | US | SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg, Epclusa | The Christ Hospital, Gilead Sciences | Hepatitis C, Pregnancy Complications, Vertical Disease Transmission | 11/22 | 02/23 | | |
NCT04039698: Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil |
|
|
| Active, not recruiting | N/A | 144 | RoW | Telemedicine, Velpatasvir/Sofosbuvir, Epclusa | Hospital de Clinicas de Porto Alegre, Ministry of Health, Brazil, State Secretary of Health of Rio Grande do Sul, TelessaúdeRS / UFRGS | Chronic Hepatitis C | 12/20 | 11/21 | | |
NCT03627546: HCV Seek, Test and Rapid Treatment for Young PWID |
|
|
| Completed | N/A | 39 | US | Rapid Treatment strategy, Usual Care (facilitated referral) | Weill Medical College of Cornell University, Gilead Sciences | Hepatitis C, Drug Use | 06/21 | 06/21 | | |
TEMPO, NCT03492112: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams |
|
|
| Completed | N/A | 101 | RoW | HCV RNA Point of Care, GeneXpert System, Sofosbuvir/velpatasvir, Epclusa, Glecaprevir/pibrentasvir, Maviret | Kirby Institute | Hepatitis C | 11/21 | 11/21 | | |
SCALE-C, NCT03776760: Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination |
|
|
| Recruiting | N/A | 600 | RoW | Fingerstick GeneXpert HCV RNA quantitative assay, sofosbuvir/velpatesvir, Epclusa, glecaprevir/pibrentasvir, Maviret | Kirby Institute, South Australian Health and Medical Research Institute, Flinders University | Hepatitis C, Hepatitis, Liver Diseases, Hepatitis, Viral, Human, RNA Virus Infections, Digestive System Diseases | 08/22 | 08/22 | | |
NCT02510300 / 2014-004674-42: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials |
|
|
| Terminated | N/A | 461 | Europe, US, RoW | Sofosbuvir (SOF), Sovaldi®, GS-7977, PSI-7977, Ledipasvir/Sofosbuvir (LDV/SOF), Harvoni®, GS-5885/GS-7977, Sofosbuvir/Velpatasvir (SOF/VEL), Epclusa®, GS-7977/GS-5816, Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX), Vosevi®, GS-7977/GS-5816/GS-9857 | Gilead Sciences | Hepatitis C Virus Infection | 01/23 | 01/23 | | |
| Not yet recruiting | N/A | 1000 | NA | Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa], Epclusa | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Gilead Sciences | Hepatitis C in Substance Users | 08/23 | 05/24 | | |
ChiCTR1900027793: Two direct antiviral drugs in the clinical effect of reverse c liver fibrosis multicenter prospectie cohort study |
|
|
| Not yet recruiting | N/A | 280 | | Grazoprevir/elbasvir ;Sofosbuvir and velpatasvir | Department of Gastroenterology, Xinqiao Hospital, Affiliated to Military Medical University; Xinqiao Hospital of Army Military University, Self-raised | Chronic hepatitis c | | | | |
NCT05248919: Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan |
|
|
| Enrolling by invitation | N/A | 318 | RoW | Epclusa (nucleotide HCV NS5B polymerase inhibitors)., Sofosbuvir 400 Mg and Velpatasvir 100 Mg Oral Capsules | Queen Mary University of London, Aga Khan University, Dow University of Health Sciences, University of Oxford, University of Bristol | Hepatitis C | 09/24 | 12/24 | | |
